Dupixent Significantly Reduced COPD Exacerbations In Second Positive Phase III Trial
The latest trial for Dupixent (dupilumab) in chronic obstructive pulmonary disease (COPD), called NOTUS, has delivered promising results. It showed a significant 34% reduction in COPD exacerbations, confirming earlier positive findings from the Phase III BOREAS trial. The study also revealed that Dupixent improved lung function rapidly within 12 weeks, and these improvements were sustained for 52 weeks.
NOTUS compared Dupixent to a placebo in adults already on maximal standard-of-care inhaled therapy (triple therapy) for COPD but experiencing uncontrolled symptoms and showing ev...
